DT-678 / Diapin Therapeutics, Beijing SL Pharma - LARVOL DELTA

A randomized, double-blind, single and multiple dose, dose escalation, placebo/positive control phase Ia clinical study evaluating the safety and PK/PD characteristics of DT678 tablets in healthy subjects (ChiCTR) - P1 | N=108 | Completed | Sponsor: Beijing Shijitan Hospital Capital Medical University; Beijing SL Pharm

New P1 trial • Cardiovascular • CYP2C19

Computational Design of CYP102A1 Variants for Biosynthesis of a Next-Generation Antiplatelet Drug DT-678. (PubMed, ACS Synth Biol) - "Clopidogrel is a widely used antiplatelet prodrug to treat acute coronary syndromes. Remarkably, we found that ascorbic acid significantly protected CYP102A1 variants from inactivation and, hence, increased production yield. This work establishes a scalable enzymatic strategy for DT-678 biosynthesis and highlights the importance of combining protein engineering with redox control to overcome limitations in CYP-catalyzed reactions."

Journal • Acute Coronary Syndrome • Cardiovascular

Promising clopidogrel analogs may overcome clopidogrel resistance: 2025 update. (PubMed, Biochem Pharmacol) - "The same strategies as those for prasugrel and vicagrel were used to design new compounds, such as tipidogrel, compound 6b, PLD-301, and W-1. All these new compounds in the pipeline are promising antiplatelet drugs, and superior to clopidogrel. DT-678 and evategrel are considered the best clopidogrel analogs that may overcome clopidogrel resistance due to their superior efficacy and safety profiles over clopidogrel."

Journal • Review